AVX-470

Phase I Active

A bovine polyclonal antibody against tumour necrosis factor alpha (TNF-α) potentially for the treatment of ulcerative colitis.

Research Code AVX-1350; AVX-470; AVX-470h

CAS No.

Vitamin D binding protein macrophage-activating factor

Phase I Active

A modified vitamin D binding protein macrophage activator potentially for the treatment of solid tumours.

Research Code EF-022; GcMAF

CAS No.

Yttrium 90-radiolabelled OTSA 101

Phase I Active

A Yttrium 90-radiolabelled antibody against frizzled homologue 10 (FZD10) potentially for the treatment of synovial sarcoma.

Research Code OTSA-101; DTPA-90Y

CAS No.

ATL-101 (ATLAB)

Phase II Active

A 177Lu-labelled anti-PSMA antibody potentially for the treatment of prostate cancer.

Research Code 177Lu-J591; 90Y-J591; huJ-591; J-591; Lu-177-J591; MLN-591RL; MLN-591; muJ-591

CAS No. 811442-46-3(MLN2704)

Recombinant hGM-CSF Herpes Simplex Virus (OrienGene Biotechnology)

Phase I Active

A recombinant herpes simplex virus 1 (HSV1) encoding human granulocyte-macrophage colony-stimulating factor (GM-CSF) potentially for the treatment of solid tumors.

Research Code OrienX-010

CAS No.

WN-1316

Phase I Active

A drug potentially for the treatment of amyotrophic lateral sclerosis (ALS).

Research Code WN-1316

CAS No. 1356959-71-1(WN-1316)  1356959-16-4(WN-1316 Free)

Malaria vaccine (Osaka University)

Phase I Active

A vaccine potentially for the prevention of falciparum malaria.

Research Code BK SE36/CpG; BK-SE36

CAS No.

SMRX-11

Phase I Active

A recombinant clot-specific streptokinase (CSSK) potentially for the treatment of thrombosis.

Research Code SMRX-11

CAS No.

Rimeporide

Phase I Active

A Na+/H+ exchanger type 1 (NHE-1) inhibitors potentially for the treatment of duchenne muscular dystrophy.

Research Code EMD-87580

CAS No. 187870-78-6(Rimeporide)

Terameprocol

(CINelim^®) Phase II Pending

A baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) inhibitor potentially for the treatment of cervical intraepithelial neoplasia, glioma and human papillomavirus infections.

Research Code EM-1421; M4N; M4NDGA; NSC-136955

CAS No. 24150-24-1(Terameprocol)

Recombinant erythropoietin (XTL)

Phase I Pending

An erythropoiesis-stimulating agent (ESA) potentially for the treatment of multiple myeloma.

Research Code EPO-XTL; rHuEPO-XTL

CAS No.

SIG-990

IND Filing Active

A Toll-like receptor (TLR) modulator potentially for the treatment of acne rosacea.

Research Code SIG-990; SIG-1311

CAS No.

ACT-1

(Granexin^®) Phase III Active

A gap junction modulator and tight junction protein modulator potentially for the treatment of diabetic foot ulcer, leg ulcer and scars.

Research Code ACT-1

CAS No.

F-598

Phase II Active

A surface antigen inhibitor potentially for the treatment of bacterial infection.

Research Code F-598; SAR-279356

CAS No.

DI-Leu16-IL2

Phase II Active

A CD20 targeted antibody-interleukin-2 fusion protein potentially for the treatment of non-Hodgkin's lymphoma.

Research Code DI-Leu16-IL2

CAS No.

Varicella zoster immune globulin (Cangene Corporation)

(Varizig^®) Approved

An immunoglobulin used to prevent varicella zoster virus infections.

Research Code

CAS No.

Hepatitis B immune globulin (Emergent BioSolutions)

(HepaGam B, ImmunoGam^®) Approved

An immunoglobulin used to treat HBV infection.

Research Code

CAS No.

Atexakin alfa

Phase II Active

A recombinant interleukin 6 (IL-6) potentially for the treatment of diabetic neuropathies and chemotherapy induced peripheral neuropathies.

Research Code r-IL-6

CAS No.

Interleukin-12 gene therapy (OncoSec Medical)

(ImmunoPulse IL-12, OMS ElectroImmunotherapy^®) Phase II Active

An interleukin-12 (IL-12) gene therapy potentially for the treatment of breast cancer, cutaneous T cell lymphoma, head and neck cancer, malignant melanoma and Merkel cell carcinoma.

Research Code DNA IL-12; pIL-12; pIL-12

CAS No.

Defibrotide sodium

(Defitelio, Noravid, Prociclide^®) Approved

A polydisperse mixture of oligonucleotides used to treat hepatic veno-occlusive disease (sinusoidal obstruction syndrome).

Research Code JZP-381

CAS No. 83712-60-1